Brookline Capital Management Estimates CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Brookline Capital Management lifted their FY2024 EPS estimates for CRISPR Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($5.16) per share for the year, up from their previous estimate of ($5.18). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.13) per share.

Other research analysts have also recently issued research reports about the company. Chardan Capital reissued a "buy" rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Needham & Company LLC reiterated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $78.38.

CRISPR Therapeutics Price Performance

CRSP stock traded down $0.63 on Thursday, reaching $41.29. The company's stock had a trading volume of 981,717 shares, compared to its average volume of 1,609,082. The firm has a fifty day moving average of $46.50 and a two-hundred day moving average of $48.88. The company has a market capitalization of $3.52 billion, a P/E ratio of -14.59 and a beta of 1.68. CRISPR Therapeutics has a 52 week low of $38.20 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the prior year, the firm earned ($1.41) EPS.

Insider Activity

In related news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. This represents a 1.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock worth $2,744,179 over the last 90 days. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in CRSP. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $35,000. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the third quarter valued at approximately $40,000. Darwin Wealth Management LLC bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. National Bank of Canada FI lifted its stake in shares of CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after buying an additional 220 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth $54,000. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.